Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8 Small Cell Lung Carcinoma 4 Colorectal Neoplasms 4 Rectal Neoplasms 3 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Colonic Neoplasms 2 Carcinoma, Intraductal, Noninfiltrating 2 Breast Carcinoma In Situ 2 Waldenstrom Macroglobulinemia 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Smoldering Multiple Myeloma 1 Pancreatic Neoplasms 1 Neoplasms, Plasma Cell 1 Margins of Excision 1 Lung Neoplasms 1 Leiomyoma 1 Fibrosis 1 Esophageal Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Brain Neoplasms 1 Biliary Tract Neoplasms 1

Interventions

telapristone acetate 10 ulipristal 3 asoprisnil 3 vilaprisan 2 estradiol, norethindrone drug combination 2 elagolix 2 Norethindrone Acetate 2 Mifepristone 2 Lidocaine 2 Leuprolide 2 Estradiol 2 ulipristal acetate 1 relugolix 1 pirfenidone 1 epigallocatechin gallate 1 Tea 1 Sugars 1 Simvastatin 1 Ropivacaine 1 Progesterone 1 Morphine 1 Methadone 1 Injections, Subcutaneous 1 Embolization, Therapeutic 1 Bupivacaine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Leiomyoma × Simvastatin × Clear all

NCT03400826 2025-07-14

Effects of Simvastatin on Uterine Leiomyoma Size

Johns Hopkins University

Phase 2 Recruiting

Leiomyoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡